Clinical Trial Update: Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating BiovaxID, a tumor-derived idiotype vaccine, in follicular lymphoma is ongoing with the trial status listed as unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• BiovaxID

Snippet

Sponsor: Biovest International | Conditions: Non-Hodgkins Lymphoma | Phase 3 | Status: UNKNOWN